<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555564</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00222311</org_study_id>
    <nct_id>NCT04555564</nct_id>
  </id_info>
  <brief_title>Tc99m Macroaggregated Albumin Bronchial Artery Study</brief_title>
  <official_title>Tc99m-Macroaggregated Albumin Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, single-center, prospective pilot study to perform bronchial artery&#xD;
      Tc-99m-MAA infusion to determine the predicted whole lung versus lung tumor dosimetry of a&#xD;
      possible intra-arterial radioembolization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm pilot study for patients presenting with hemoptysis&#xD;
      from lung cancers. Prior to a therapeutic bronchial artery embolization (standard therapy),&#xD;
      Tc99m-MAA will be administered to the bronchial artery and an imaging will be obtained to&#xD;
      determine the distribution of MAA.&#xD;
&#xD;
      The primary objective will be quantification of Tc99m-MAA uptake within the tumor and&#xD;
      surrounding structures (esophagus, bronchi, pericardium, spine). This is a purely descriptive&#xD;
      study and no statistical comparison or correlation will be made. Dosimetry will be reported&#xD;
      for each patient, as well as range and mean with standard deviation. Additional activity&#xD;
      calculation methods and reporting metrics may additionally be used. Non-statistical&#xD;
      comparison will be made to literature-reported external-beam radiation dose-related tumor&#xD;
      response and adjacent-organ toxicities to develop a preliminary assessment of the potential&#xD;
      for efficacy and anticipated safety-profile of Yittrium-90 bronchial artery&#xD;
      radio-embolization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, prospective, single-center</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of Tc99m-MAA uptake</measure>
    <time_frame>12 months</time_frame>
    <description>The primary objective will be quantification of Tc99m-MAA uptake (measured in &quot;Gray&quot;) within the tumor and surrounding structures (esophagus, bronchi, pericardium, spine). This is a purely descriptive study and no statistical comparison or correlation will be made. This assessment will be done for each participant at 12 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hemoptysis</condition>
  <condition>Malignant Neoplasm</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Technicium 99 MAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive bronchial artery administration of Technicium 99 MAA</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Technicium 99 MAA infusion</intervention_name>
    <description>4mci of Technicium 99 MAA will be infused into the bronchial artery via a catheter prior to a standard therapy (bronchial artery embolization). The patient will undergo nuclear medicine imaging following this intervention to quantify MAA distribution within the lung tumor and adjacent lung tissue.</description>
    <arm_group_label>Technicium 99 MAA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects 18 years of age and older&#xD;
&#xD;
          -  Patients with known active lung cancer with a history of prior hemoptysis presenting&#xD;
             for bronchial artery embolization will be considered.&#xD;
&#xD;
          -  Patients must be presenting for secondary prophylaxis of hemoptysis&#xD;
&#xD;
          -  Willing and able to understand and sign a written informed consent document.&#xD;
&#xD;
          -  Willing and able to undergo all study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with current active hemoptysis&#xD;
&#xD;
          -  Any acute or chronic inflammatory disease or medical conditions that in the&#xD;
             investigator's opinion may interfere with the study procedures or the interpretation&#xD;
             of the study results.&#xD;
&#xD;
          -  If female, not of childbearing potential or negative serum β-human chorionic&#xD;
             gonadotropin pregnancy test prior to radiotracer injection.&#xD;
&#xD;
          -  If female, not nursing.&#xD;
&#xD;
          -  Subjects who have exclusion criteria that would prevent them from receiving a CT scan&#xD;
             or fluoroscopy, or administration of contrast.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to macro-aggregated albumin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Buethe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Buethe, MD</last_name>
    <phone>410-614-5182</phone>
    <email>jbuethe1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Kohler, RN, MPH, MBA</last_name>
    <phone>410 614 4212</phone>
    <email>bkohler@jhmi.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Chun JY, Belli AM. Immediate and long-term outcomes of bronchial and non-bronchial systemic artery embolisation for the management of haemoptysis. Eur Radiol. 2010 Mar;20(3):558-65. doi: 10.1007/s00330-009-1591-3. Epub 2009 Sep 2.</citation>
    <PMID>19727742</PMID>
  </reference>
  <reference>
    <citation>Wang GR, Ensor JE, Gupta S, Hicks ME, Tam AL. Bronchial artery embolization for the management of hemoptysis in oncology patients: utility and prognostic factors. J Vasc Interv Radiol. 2009 Jun;20(6):722-9. doi: 10.1016/j.jvir.2009.02.016. Epub 2009 May 5.</citation>
    <PMID>19406667</PMID>
  </reference>
  <reference>
    <citation>Swanson KL, Johnson CM, Prakash UB, McKusick MA, Andrews JC, Stanson AW. Bronchial artery embolization : experience with 54 patients. Chest. 2002 Mar;121(3):789-95.</citation>
    <PMID>11888961</PMID>
  </reference>
  <reference>
    <citation>Eldridge L, Moldobaeva A, Zhong Q, Jenkins J, Snyder M, Brown RH, Mitzner W, Wagner EM. Bronchial Artery Angiogenesis Drives Lung Tumor Growth. Cancer Res. 2016 Oct 15;76(20):5962-5969. Epub 2016 Aug 28.</citation>
    <PMID>27569207</PMID>
  </reference>
  <reference>
    <citation>Jonas AM, Carrington CB. Vascular patterns in primary and secondary pulmonary tumors in the dog. Am J Pathol. 1969 Jul;56(1):79-95.</citation>
    <PMID>4893319</PMID>
  </reference>
  <reference>
    <citation>CUDKOWICZ L, ARMSTRONG JB. The blood supply of malignant pulmonary neoplasms. Thorax. 1953 Jun;8(2):153-6.</citation>
    <PMID>13077512</PMID>
  </reference>
  <reference>
    <citation>Ricke J, Großer O, Amthauer H. Y90-radioembolization of lung metastases via the bronchial artery: a report of 2 cases. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1664-1669. doi: 10.1007/s00270-013-0690-3. Epub 2013 Jul 10.</citation>
    <PMID>23839007</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>lung metastasis</keyword>
  <keyword>Bronchial artery embolization</keyword>
  <keyword>MAA study</keyword>
  <keyword>Dosimetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hemoptysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

